David McLain, MD
Rheumatology · Birmingham, ALNPI 1689614737
Payments from drug & device makers
Across 1,685 payments — averaging $348.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$557K
- Amgen$5K
- UCB, Inc.$3K
- GSK$3K
- Pfizer$3K
- Novartis$2K
- plus $15K from 51 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$587,905 in reported general payments places this provider in the 90th percentile of 90 rheumatology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Birmingham
- Jeffrey CurtisBirmingham$17.6M
- Kenneth SaagBirmingham$8.2M
- Harry SchroederBirmingham$938K
- Jose Rubio MosqueraBirmingham$823K
- Maria DanilaBirmingham$196K
- James AndrewsBirmingham$192K
- Angelo Gaffo LlontopBirmingham$182K
- Matthew MullenBirmingham$38K
- Greg EudyBirmingham$33K
- John MorganBirmingham$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.